Vivus sells Muse to Meda

Vivus Inc. (NASDAQ:VVUS) will divest all assets related to erectile dysfunction (ED) drug Muse alprostadil to partner Meda AB (SSE:MEDAA) for $22 million up front in cash and a potential milestone payment of $1.5 million. Meda already has European rights to the pellet placed in the urinary opening to self-dispense the vasoactive drugs alprostadil and/or prazosin HCI. Meda said Muse has annual U.S. sales of about $15 million. The deal is expected to close on or before Nov. 15. ...